Kiora Pharmaceuticals Inc (KPRX) stock
KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
$0.82−0.11 (-11.31%)
Close on Nov 18, 2026Market cap $3.65MP/E –Yield –
Kiora Pharmaceuticals net income
Net income is the profit left for shareholders after every expense, interest and tax.
Kiora Pharmaceuticals's net income for the twelve months ending Jun 30, 2026 was -$10.99M. For fiscal 2025 it was -$10.84M, down 401.4% from the year before. The highest annual figure on record is $3.59M in fiscal 2024.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.84M | -401.4% |
| FY2024 | Dec 31, 2024 | $3.59M | – |
| FY2023 | Dec 31, 2023 | -$12.51M | – |
| FY2022 | Dec 31, 2022 | -$13.58M | – |
| FY2021 | Dec 31, 2021 | -$13.77M | – |
| FY2020 | Dec 31, 2020 | -$6.86M | – |
| FY2019 | Dec 31, 2019 | -$7.10M | – |
| FY2018 | Dec 31, 2018 | -$10.81M | – |
| FY2017 | Dec 31, 2017 | -$13.22M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.52M | – |
| Q3 FY2025 | Sep 30, 2025 | $26.81K | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.19M | -116.3% |
| Q4 FY2024 | Dec 31, 2024 | -$4.22M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.22M | – |
| Q1 FY2024 | Mar 31, 2024 | $13.45M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.76M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.50M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.03M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.01M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.19M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.72M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.95M | -324.2% |
| Q4 FY2019 | Dec 31, 2019 | -$2.70M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.84M | – |
| Q1 FY2019 | Mar 31, 2019 | $870.81K | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.53M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.12M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.78M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.38M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.14M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.33M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.92M | – |
See a number that looks wrong?